I think the evidence speaks for itself. Of the 15 new antibiotic entities that have been brought to market over the last 10 years, we have access to only three. That's not a great ratio.
There are a number of reasons for that. For one of them, I think we have to remember that Canada is a very small market for these drug companies. The barriers to entry for bringing an antibiotic that has received approval by the FDA, say, or the EMA, for example, into Health Canada involve some bureaucracy. That bureaucracy, I think, has to be measured against the potential market size in Canada and the distribution across this great, vast country. That is part of the issue that's being faced.
Of course, what we want to do is ensure that all the barriers to getting these medicines to Canadians are reasonably removed, so that we're not artificially stacking the cards against ourselves.